医药生物行业周报：印发《关于解决拖欠企业账款问题的意见》，企业应收账款回款有望缓解

Investment Rating - The report maintains an "Overweight" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The issuance of the "Opinions on Resolving the Issue of Arrears in Corporate Accounts Receivable" is expected to alleviate the collection of accounts receivable for enterprises [5][6]. - The recent statements from the Ministry of Finance and the release of the "Opinions" will significantly ease local financial pressures, positively impacting the collection of accounts receivable for companies [5]. Market Review - During the week of October 14-18, 2024, the A-share pharmaceutical and biotechnology sector rose by 1.04%, outperforming the CSI 300 index by 0.06 percentage points but underperforming the ChiNext index by 5.81 percentage points [6]. - The Hang Seng Healthcare Index fell by 4.17%, lagging behind the Hang Seng Index by 2.06 percentage points [6]. - The top five gainers in the A-share pharmaceutical sector included Shuangcheng Pharmaceutical (+60.97%), Micron Technology (+58.4%), and Changshan Pharmaceutical (+49.75%) [6]. Company Dynamics Company Announcements - Xianju Pharmaceutical received a production registration acceptance notice for a drug from the National Medical Products Administration on October 17, 2024 [8]. - Shanghai Yizhong's core product, injectable paclitaxel polymer micelles, has received clinical trial approval for a new indication of pancreatic cancer [8]. - Lepu Medical's non-invasive blood glucose meter has been approved by the National Medical Products Administration [8]. Financing Dynamics - Nanjing Pharmaceutical has received approval for a convertible bond issuance with a scale of 1.08149 billion yuan [9]. Unlocking Dynamics - Kangzhi Pharmaceutical had 512.44 million shares unlocked on October 14, 2024, with a market value of 24.19 million yuan [10].